New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2010, Pages 379-382

  Martin Carbonero, Luz ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug resistance; Liver; Tenofovir; Vaccine escape mutants

Indexed keywords

ABACAVIR; ADEFOVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIGENICITY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OUTCOME ASSESSMENT; PHOSPHORYLATION; PROGNOSIS; SERODIAGNOSIS; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 77950312767     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp492     Document Type: Article

References (34)

1. Konopnicki D, Mocroft A, de Wit S. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 2117-25.
2. Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9: 25-39.
3. Thio C, Seaberg E, Skolasky R et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 1921-6.
4. Hoffmann C, Seaberg E, Young S et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-9.
5. Idoko J, Meloni S, Muazu M et al. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49: 1268-73.
6. Dore G, Soriano V, Rockstroh J et al. Frequent hepatitis B virus (HBV) rebound among HIV-HBV coinfected patients following antiretroviral therapy interruption in the SMART study. Hepatology 2010; in press.
7. Soriano V, Sheldon J, Ramos B et al. Confronting hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS 2006; 20: 451-3.
8. Soriano V, Puoti M, Peters M et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22: 1399-410.
9. Iloeje U, Yang H, Jen C et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921-31.
10. Lok A, McMahon B. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
11. Hammer S, Eron J, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
12. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. www.aidsinfo.nih.gov (30 November 2009, date last accessed).
13. Marcellin P, Heathcote J, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
14. Benhamou Y, Fleury H, Trimoulet P et al. Antihepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
15. Sheldon J, Camino N, RodésB. et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-34.
16. Audsley J, Arrifin N, Yuen L et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med 2009; 10: 229-35.
17. Lim S, Ng T, Kung N et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Inter Med 2006; 166: 49-56.
18. Carey I, Harrison P. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009; 18: 1655-66.
19. Hoffmann C, Charalambous S, Martin D et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47: 1479-85.
20. Matthews G, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-70.
21. Thio C, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virological issues. AIDS Rev 2007; 9: 40-53.
22. Karatayli E, Karayalcin S, Karaaslan H et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12: 761-8.
23. Tuma P, Soriano V, Bottecchia M et al. Prevalence of primary drug resistance in hepatitis B virus in newly diagnosed HIV patients with chronic hepatitis B in Spain: a national cohort. In: Abstracts of the Twelfth European AIDS Conference, Cologne, Germany, 2009. Abstract PS2/7. HIV Med 2009; 10 Suppl 2: 3.
24. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-8.
25. Hsu C, Yeh C, Chang M et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132: 543-50.
26. Westhoff T, Jochimsen S, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
27. Awerkiew S, Daumer M, Reiser M et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38:83-6.
28. Torresi J. Hepatitis B antiviral resistance and vaccine escape: two sides of the same coin. Antivir Ther 2008; 13: 337-40.
29. McMahon M, Jilek B, Brennan T et al. The HBV drug entecavir: effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-21.
30. Barreiro P, García-Benayas T, Rendon AL et al. Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev 2004; 6: 234-43.
31. Low E, Cox A, Atkins M et al. Telbivudine has activity against HIV-1. AIDS 2009; 23: 546-7.
32. Sheldon J, Corral A, Rodes B et al. Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19: 2036-8.
33. Maida I, Soriano V, Castellares C et al. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006; 7: 246-50.
34. Mallet V, Dhalluin-Venier V, Verkarre V et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 2007; 12: 279-83.